Mechanism

How it works

BPC-157 upregulates growth hormone receptor expression, promotes nitric oxide synthesis via the eNOS pathway, and stimulates VEGF-driven angiogenesis to accelerate tissue vascularization and repair. TB-500 (a synthetic analogue of the Thymosin Beta-4 protein's active region, Ac-SDKP) sequesters G-actin, promotes cell migration and differentiation, and independently activates angiogenic and anti-inflammatory cascades. Together they act synergistically: BPC-157 anchors local tissue repair and gut-brain axis modulation while TB-500 drives systemic cellular migration and cytoskeletal remodeling, producing complementary and potentially additive healing outcomes.

Reported in research

Benefits

Accelerated tendon, ligament, and muscle tissue repair compared to either peptide alone
Enhanced angiogenesis supporting nutrient delivery to injured tissue sites
Systemic and local reduction of inflammation, potentially reducing recovery time from acute injuries
Convenience of a single combined vial reducing preparation complexity and injection frequency

Context, not a prescription

Dosing

Typical range: 250 mcg BPC-157 + 250 mcg TB-500 per injection (from the blend), once daily or 5x/week (Subcutaneous, Intramuscular)
Cycle length: 4-8 weeks
Half-life: BPC-157: ~4 hours; TB-500: ~several days (estimated)

Safety

Side effects & contraindications

Possible side effects

Mild nausea or gastrointestinal discomfort (primarily attributed to BPC-157 component)
Injection site redness, swelling, or mild pain
Transient dizziness or lightheadedness shortly after injection
Theoretical concern of promoting growth in pre-existing neoplastic tissue (largely theoretical, unconfirmed in humans)

Contraindications

Active malignancy or personal/family history of cancer (theoretical angiogenic risk)
Pregnancy or breastfeeding (no safety data available)
Known hypersensitivity to either BPC-157 or Thymosin Beta-4 components
Concurrent use of anticoagulants without medical supervision

Research information, not medical advice. Always consult a licensed clinician before considering any peptide.

In depth

Full profile

What it does

You may notice reduced pain and swelling at injury sites, improved mobility and flexibility, faster gym recovery between sessions, and in some cases improved gut comfort.

How it works

Imagine your body is a city after an earthquake. BPC-157 is like the local construction crew rebuilding the roads and water lines in the damaged neighborhood, while TB-500 is like a national emergency broadcast that calls skilled workers from across the entire country to come help. Together, the repair happens faster and more completely.

Both peptides are injected just under the skin or into muscle tissue. They travel through your bloodstream to sites of injury or inflammation, where they interact with cells to encourage new blood vessel growth, reduce swelling, and speed up tissue knitting. BPC-157 tends to have stronger gut and local effects, while TB-500 works more throughout the entire body.

What to expect

Many users report reduced soreness and early signs of healing within 1-2 weeks of consistent use. Structural tissue repair (tendons, ligaments) typically requires 4-8 weeks to become meaningfully noticeable.

Week 1: Peptides begin circulating; some users notice mild reduction in acute inflammation or soreness. Injection site tolerance is being established.
Weeks 2-4: Angiogenesis and cellular repair activity is ramping up. Many users report noticeably reduced pain, improved range of motion, and faster post-workout recovery.
Weeks 4-8: Structural tissue healing becomes more apparent. Tendons and ligaments may feel more resilient. Full benefits are typically assessed at or after this point before deciding to continue or cycle off.

Good to know

Always reconstitute with sterile bacteriostatic water and use clean injection technique to avoid infection
Start with a lower dose (e.g., 200 mcg of the blend) to assess personal tolerance before increasing

Staying safe

Mild upset stomach or nausea, especially with BPC-157
Small lump, redness, or mild soreness at the injection site

Avoid if you have:

Anyone with an active cancer diagnosis or strong cancer family history
Pregnant or breastfeeding individuals
Competitive athletes subject to WADA drug testing

Overview

Expected physiological changes include upregulated VEGF expression at repair sites (measurable in theory via tissue biopsy), increased collagen deposition and organization in tendons, enhanced Type I and Type III collagen synthesis ratios, improved myofibroblast activity, and normalized inflammatory cytokine profiles (reduced TNF-α, IL-6 in injured tissue). Systemic anti-inflammatory effects may manifest as reduced CRP and ESR in some users, though this is primarily animal-derived inference.

How it works

BPC-157 and TB-500 are like two independent electrical circuits both wired to the same set of lights — tissue repair and angiogenesis. BPC-157 routes through the eNOS/NO and FAK-paxillin switch, while TB-500 routes through the ILK/Akt/PI3K switch. Flipping both switches simultaneously produces brighter illumination (more robust repair signaling) than either switch alone, even though their upstream wiring is completely different.

Following subcutaneous or intramuscular administration, BPC-157 demonstrates remarkable stability against enzymatic degradation in gastric juice and plasma — a property that distinguishes it from most peptides of similar size. TB-500's synthetic active fragment distributes systemically and has been detected in tissue remodeling contexts including cardiac, musculoskeletal, and dermal repair in rodent models. The combination exploits the local repair optimization of BPC-157 with the systemic homing properties of TB-500's actin-sequestering mechanism, potentially achieving tissue healing outcomes superior to either agent alone at equivalent doses.

Onset & timeline

Pharmacokinetically, BPC-157 reaches peak plasma concentration within 15-30 minutes post-injection with an estimated half-life of ~4 hours, necessitating daily dosing for sustained effect. TB-500's active fragment has a substantially longer estimated half-life (days to possibly a week), allowing less frequent dosing once a loading phase is completed. In animal models, measurable changes in wound tensile strength and vascular density have been observed within 48-72 hours of dosing initiation.

Days 1-3: BPC-157 achieves steady-state plasma cycling within 24 hours of daily dosing. TB-500 fragment begins accumulating in systemic circulation. eNOS activation and initial G-actin sequestration occur, with early pro-angiogenic signaling initiated at injury loci.
Weeks 1-2: Measurable angiogenesis begins (new capillary formation observable in animal models within 7 days). Collagen synthesis upregulation is underway. Inflammatory cytokine profiles shift toward resolution phase (IL-10 upregulation, TNF-α downregulation). Clinically, subjective pain reduction and improved range of motion are often the first user-reported outcomes.
Weeks 2-8: Ongoing collagen remodeling and matrix organization. Tendon and ligament tensile strength increases progressively. VEGF-driven vascularization matures, improving nutrient delivery to previously ischemic injury zones. For chronic injuries, structural remodeling may continue beyond the dosing cycle due to the cascade of cellular events initiated. Assessment of outcomes and cycle-off decision typically made at week 8.

Getting the most from it

Conduct baseline bloodwork (CBC, CMP, inflammatory markers) before initiating a cycle to establish reference values and detect any contraindicated conditions
Use a loading protocol for TB-500 component (higher dose for 2 weeks, then maintenance) rather than a flat daily dose to leverage its longer half-life and reduce total peptide quantity used
Reconstitute with bacteriostatic water (0.9% benzyl alcohol) rather than plain sterile water to maximize post-reconstitution stability and reduce microbial contamination risk

Common side effects

GI motility changes or nausea due to BPC-157's enteric nervous system activity (dose-dependent, typically mild)
Transient local inflammatory response at injection site from peptide-induced immune cell chemotaxis

Mechanism of action

BPC-157 is a 15-amino-acid partial sequence of the body's own gastric protective protein. It upregulates eNOS (endothelial nitric oxide synthase), activates the FAK-paxillin pathway to enhance cell spreading and migration, modulates dopaminergic and serotonergic neurotransmission via the brain-gut axis, and stimulates VEGF (Vascular Endothelial Growth Factor) to drive robust angiogenesis at wound sites. TB-500 is a synthetic peptide corresponding to the actin-sequestering domain of Thymosin Beta-4 (residues 17-23, Ac-SDKP and surrounding sequence). It binds G-actin with high affinity, reducing the pool available for F-actin polymerization, thereby modulating cytoskeletal dynamics. This promotes keratinocyte and endothelial cell migration. TB-500 also activates ILK (Integrin-Linked Kinase) and downstream Akt/PI3K signaling, enhancing cell survival, proliferation, and independently stimulating VEGF expression. The two peptides converge on VEGF upregulation via distinct upstream pathways, suggesting mechanistic synergy rather than simple redundancy.

Following subcutaneous or intramuscular administration, BPC-157 demonstrates remarkable stability against enzymatic degradation in gastric juice and plasma — a property that distinguishes it from most peptides of similar size. TB-500's synthetic active fragment distributes systemically and has been detected in tissue remodeling contexts including cardiac, musculoskeletal, and dermal repair in rodent models. The combination exploits the local repair optimization of BPC-157 with the systemic homing properties of TB-500's actin-sequestering mechanism, potentially achieving tissue healing outcomes superior to either agent alone at equivalent doses.

Pharmacodynamics

Pharmacokinetically, BPC-157 reaches peak plasma concentration within 15-30 minutes post-injection with an estimated half-life of ~4 hours, necessitating daily dosing for sustained effect. TB-500's active fragment has a substantially longer estimated half-life (days to possibly a week), allowing less frequent dosing once a loading phase is completed. In animal models, measurable changes in wound tensile strength and vascular density have been observed within 48-72 hours of dosing initiation.

Expected physiological changes include upregulated VEGF expression at repair sites (measurable in theory via tissue biopsy), increased collagen deposition and organization in tendons, enhanced Type I and Type III collagen synthesis ratios, improved myofibroblast activity, and normalized inflammatory cytokine profiles (reduced TNF-α, IL-6 in injured tissue). Systemic anti-inflammatory effects may manifest as reduced CRP and ESR in some users, though this is primarily animal-derived inference.

Timeline

Days 1-3: BPC-157 achieves steady-state plasma cycling within 24 hours of daily dosing. TB-500 fragment begins accumulating in systemic circulation. eNOS activation and initial G-actin sequestration occur, with early pro-angiogenic signaling initiated at injury loci.
Weeks 1-2: Measurable angiogenesis begins (new capillary formation observable in animal models within 7 days). Collagen synthesis upregulation is underway. Inflammatory cytokine profiles shift toward resolution phase (IL-10 upregulation, TNF-α downregulation). Clinically, subjective pain reduction and improved range of motion are often the first user-reported outcomes.
Weeks 2-8: Ongoing collagen remodeling and matrix organization. Tendon and ligament tensile strength increases progressively. VEGF-driven vascularization matures, improving nutrient delivery to previously ischemic injury zones. For chronic injuries, structural remodeling may continue beyond the dosing cycle due to the cascade of cellular events initiated. Assessment of outcomes and cycle-off decision typically made at week 8.

Comparisons

BPC-157 + TB-500 Blend — effectiveness High, safety Good, cost $$$, Medium to use
BPC-157 Standalone — effectiveness High, safety Good, cost $$, Medium to use
TB-500 Standalone — effectiveness Moderate, safety Good, cost $$, Medium to use
GHK-Cu — effectiveness Moderate, safety Excellent, cost $$, Medium to use
IGF-1 LR3 — effectiveness High, safety Moderate, cost $$$, Low to use

Adverse effects

Common:

GI motility changes or nausea due to BPC-157's enteric nervous system activity (dose-dependent, typically mild)
Transient local inflammatory response at injection site from peptide-induced immune cell chemotaxis

Rare:

Theoretical promotion of angiogenesis in occult or pre-existing neoplastic tissue — no confirmed human cases but mechanistically plausible given VEGF upregulation
Rare reports of transient orthostatic hypotension potentially related to NO pathway activation by BPC-157

Contraindications & risk mitigation

Contraindicated in:

Patients with confirmed or suspected malignancy, given dual VEGF upregulation by both components
Individuals with active autoimmune conditions where modulating immune cell migration could be unpredictable
Patients on systemic anticoagulation therapy where angiogenic activity could complicate hemostasis

Conduct baseline bloodwork (CBC, CMP, inflammatory markers) before initiating a cycle to establish reference values and detect any contraindicated conditions
Use a loading protocol for TB-500 component (higher dose for 2 weeks, then maintenance) rather than a flat daily dose to leverage its longer half-life and reduce total peptide quantity used
Reconstitute with bacteriostatic water (0.9% benzyl alcohol) rather than plain sterile water to maximize post-reconstitution stability and reduce microbial contamination risk

Qué hace

You may notice reduced pain and swelling at injury sites, improved mobility and flexibility, faster gym recovery between sessions, and in some cases improved gut comfort.

Cómo funciona

Imagine your body is a city after an earthquake. BPC-157 is like the local construction crew rebuilding the roads and water lines in the damaged neighborhood, while TB-500 is like a national emergency broadcast that calls skilled workers from across the entire country to come help. Together, the repair happens faster and more completely.

Both peptides are injected just under the skin or into muscle tissue. They travel through your bloodstream to sites of injury or inflammation, where they interact with cells to encourage new blood vessel growth, reduce swelling, and speed up tissue knitting. BPC-157 tends to have stronger gut and local effects, while TB-500 works more throughout the entire body.

Qué esperar

Many users report reduced soreness and early signs of healing within 1-2 weeks of consistent use. Structural tissue repair (tendons, ligaments) typically requires 4-8 weeks to become meaningfully noticeable.

Week 1: Peptides begin circulating; some users notice mild reduction in acute inflammation or soreness. Injection site tolerance is being established.
Weeks 2-4: Angiogenesis and cellular repair activity is ramping up. Many users report noticeably reduced pain, improved range of motion, and faster post-workout recovery.
Weeks 4-8: Structural tissue healing becomes more apparent. Tendons and ligaments may feel more resilient. Full benefits are typically assessed at or after this point before deciding to continue or cycle off.

Bueno saber

Always reconstitute with sterile bacteriostatic water and use clean injection technique to avoid infection
Start with a lower dose (e.g., 200 mcg of the blend) to assess personal tolerance before increasing

Manteniéndose seguro

Mild upset stomach or nausea, especially with BPC-157
Small lump, redness, or mild soreness at the injection site

Evitar si tienes:

Anyone with an active cancer diagnosis or strong cancer family history
Pregnant or breastfeeding individuals
Competitive athletes subject to WADA drug testing

Descripción general

Expected physiological changes include upregulated VEGF expression at repair sites (measurable in theory via tissue biopsy), increased collagen deposition and organization in tendons, enhanced Type I and Type III collagen synthesis ratios, improved myofibroblast activity, and normalized inflammatory cytokine profiles (reduced TNF-α, IL-6 in injured tissue). Systemic anti-inflammatory effects may manifest as reduced CRP and ESR in some users, though this is primarily animal-derived inference.

Cómo funciona

BPC-157 and TB-500 are like two independent electrical circuits both wired to the same set of lights — tissue repair and angiogenesis. BPC-157 routes through the eNOS/NO and FAK-paxillin switch, while TB-500 routes through the ILK/Akt/PI3K switch. Flipping both switches simultaneously produces brighter illumination (more robust repair signaling) than either switch alone, even though their upstream wiring is completely different.

Following subcutaneous or intramuscular administration, BPC-157 demonstrates remarkable stability against enzymatic degradation in gastric juice and plasma — a property that distinguishes it from most peptides of similar size. TB-500's synthetic active fragment distributes systemically and has been detected in tissue remodeling contexts including cardiac, musculoskeletal, and dermal repair in rodent models. The combination exploits the local repair optimization of BPC-157 with the systemic homing properties of TB-500's actin-sequestering mechanism, potentially achieving tissue healing outcomes superior to either agent alone at equivalent doses.

Inicio y cronología

Pharmacokinetically, BPC-157 reaches peak plasma concentration within 15-30 minutes post-injection with an estimated half-life of ~4 hours, necessitating daily dosing for sustained effect. TB-500's active fragment has a substantially longer estimated half-life (days to possibly a week), allowing less frequent dosing once a loading phase is completed. In animal models, measurable changes in wound tensile strength and vascular density have been observed within 48-72 hours of dosing initiation.

Days 1-3: BPC-157 achieves steady-state plasma cycling within 24 hours of daily dosing. TB-500 fragment begins accumulating in systemic circulation. eNOS activation and initial G-actin sequestration occur, with early pro-angiogenic signaling initiated at injury loci.
Weeks 1-2: Measurable angiogenesis begins (new capillary formation observable in animal models within 7 days). Collagen synthesis upregulation is underway. Inflammatory cytokine profiles shift toward resolution phase (IL-10 upregulation, TNF-α downregulation). Clinically, subjective pain reduction and improved range of motion are often the first user-reported outcomes.
Weeks 2-8: Ongoing collagen remodeling and matrix organization. Tendon and ligament tensile strength increases progressively. VEGF-driven vascularization matures, improving nutrient delivery to previously ischemic injury zones. For chronic injuries, structural remodeling may continue beyond the dosing cycle due to the cascade of cellular events initiated. Assessment of outcomes and cycle-off decision typically made at week 8.

Cómo aprovecharlo al máximo

Conduct baseline bloodwork (CBC, CMP, inflammatory markers) before initiating a cycle to establish reference values and detect any contraindicated conditions
Use a loading protocol for TB-500 component (higher dose for 2 weeks, then maintenance) rather than a flat daily dose to leverage its longer half-life and reduce total peptide quantity used
Reconstitute with bacteriostatic water (0.9% benzyl alcohol) rather than plain sterile water to maximize post-reconstitution stability and reduce microbial contamination risk

Efectos secundarios comunes

GI motility changes or nausea due to BPC-157's enteric nervous system activity (dose-dependent, typically mild)
Transient local inflammatory response at injection site from peptide-induced immune cell chemotaxis

Mecanismo de acción

BPC-157 is a 15-amino-acid partial sequence of the body's own gastric protective protein. It upregulates eNOS (endothelial nitric oxide synthase), activates the FAK-paxillin pathway to enhance cell spreading and migration, modulates dopaminergic and serotonergic neurotransmission via the brain-gut axis, and stimulates VEGF (Vascular Endothelial Growth Factor) to drive robust angiogenesis at wound sites. TB-500 is a synthetic peptide corresponding to the actin-sequestering domain of Thymosin Beta-4 (residues 17-23, Ac-SDKP and surrounding sequence). It binds G-actin with high affinity, reducing the pool available for F-actin polymerization, thereby modulating cytoskeletal dynamics. This promotes keratinocyte and endothelial cell migration. TB-500 also activates ILK (Integrin-Linked Kinase) and downstream Akt/PI3K signaling, enhancing cell survival, proliferation, and independently stimulating VEGF expression. The two peptides converge on VEGF upregulation via distinct upstream pathways, suggesting mechanistic synergy rather than simple redundancy.

Following subcutaneous or intramuscular administration, BPC-157 demonstrates remarkable stability against enzymatic degradation in gastric juice and plasma — a property that distinguishes it from most peptides of similar size. TB-500's synthetic active fragment distributes systemically and has been detected in tissue remodeling contexts including cardiac, musculoskeletal, and dermal repair in rodent models. The combination exploits the local repair optimization of BPC-157 with the systemic homing properties of TB-500's actin-sequestering mechanism, potentially achieving tissue healing outcomes superior to either agent alone at equivalent doses.

Farmacodinamia

Pharmacokinetically, BPC-157 reaches peak plasma concentration within 15-30 minutes post-injection with an estimated half-life of ~4 hours, necessitating daily dosing for sustained effect. TB-500's active fragment has a substantially longer estimated half-life (days to possibly a week), allowing less frequent dosing once a loading phase is completed. In animal models, measurable changes in wound tensile strength and vascular density have been observed within 48-72 hours of dosing initiation.

Expected physiological changes include upregulated VEGF expression at repair sites (measurable in theory via tissue biopsy), increased collagen deposition and organization in tendons, enhanced Type I and Type III collagen synthesis ratios, improved myofibroblast activity, and normalized inflammatory cytokine profiles (reduced TNF-α, IL-6 in injured tissue). Systemic anti-inflammatory effects may manifest as reduced CRP and ESR in some users, though this is primarily animal-derived inference.

Cronología

Days 1-3: BPC-157 achieves steady-state plasma cycling within 24 hours of daily dosing. TB-500 fragment begins accumulating in systemic circulation. eNOS activation and initial G-actin sequestration occur, with early pro-angiogenic signaling initiated at injury loci.
Weeks 1-2: Measurable angiogenesis begins (new capillary formation observable in animal models within 7 days). Collagen synthesis upregulation is underway. Inflammatory cytokine profiles shift toward resolution phase (IL-10 upregulation, TNF-α downregulation). Clinically, subjective pain reduction and improved range of motion are often the first user-reported outcomes.
Weeks 2-8: Ongoing collagen remodeling and matrix organization. Tendon and ligament tensile strength increases progressively. VEGF-driven vascularization matures, improving nutrient delivery to previously ischemic injury zones. For chronic injuries, structural remodeling may continue beyond the dosing cycle due to the cascade of cellular events initiated. Assessment of outcomes and cycle-off decision typically made at week 8.

Comparaciones

BPC-157 + TB-500 Blend — efectividad High, seguridad Good, costo $$$, Medium de usar
BPC-157 Standalone — efectividad High, seguridad Good, costo $$, Medium de usar
TB-500 Standalone — efectividad Moderate, seguridad Good, costo $$, Medium de usar
GHK-Cu — efectividad Moderate, seguridad Excellent, costo $$, Medium de usar
IGF-1 LR3 — efectividad High, seguridad Moderate, costo $$$, Low de usar

Efectos adversos

Comunes:

GI motility changes or nausea due to BPC-157's enteric nervous system activity (dose-dependent, typically mild)
Transient local inflammatory response at injection site from peptide-induced immune cell chemotaxis

Raros:

Theoretical promotion of angiogenesis in occult or pre-existing neoplastic tissue — no confirmed human cases but mechanistically plausible given VEGF upregulation
Rare reports of transient orthostatic hypotension potentially related to NO pathway activation by BPC-157

Contraindicaciones y mitigación de riesgos

Contraindicado en:

Patients with confirmed or suspected malignancy, given dual VEGF upregulation by both components
Individuals with active autoimmune conditions where modulating immune cell migration could be unpredictable
Patients on systemic anticoagulation therapy where angiogenic activity could complicate hemostasis

Conduct baseline bloodwork (CBC, CMP, inflammatory markers) before initiating a cycle to establish reference values and detect any contraindicated conditions
Use a loading protocol for TB-500 component (higher dose for 2 weeks, then maintenance) rather than a flat daily dose to leverage its longer half-life and reduce total peptide quantity used
Reconstitute with bacteriostatic water (0.9% benzyl alcohol) rather than plain sterile water to maximize post-reconstitution stability and reduce microbial contamination risk

Reference data

Specifications

Molecular formula: BPC-157: C62H98N16O22; TB-500 (Ac-SDKP fragment active region): C14H24N4O9 (approximate active peptide)
Molecular weight: BPC-157: ~1419.5 Da; TB-500 (synthetic fragment): ~43 Da active sequence; full Thymosin Beta-4: ~4963 Da
Half-life: BPC-157: ~4 hours; TB-500: ~several days (estimated)
Route: Subcutaneous, Intramuscular
Cycle length: 4-8 weeks
Storage: Lyophilized (dry) powder: store at 2–8°C (refrigerated) away from light; stable up to 24 months lyophilized. After reconstitution with bacteriostatic water: store at 2–8°C, use within 28–30 days. Do not freeze reconstituted solution.
Legal status: Not approved by FDA or EMA for human use. Legal to purchase for research purposes in most countries. Classified as a Research Chemical. Banned by WADA in competitive sports.

FAQ

Common questions

Is there pharmacological justification for combining BPC-157 and TB-500, or is the synergy just marketing?

There is mechanistic justification: BPC-157 primarily signals through eNOS/NO and FAK-paxillin pathways, while TB-500 signals through ILK/Akt/PI3K and G-actin sequestration. Both independently upregulate VEGF but via different upstream mechanisms. This suggests genuine pathway complementarity rather than simple redundancy. However, formal combination pharmacology studies in animals are limited, and no human trials have assessed the combination directly.

Should the BPC-157 and TB-500 be dosed at equal ratios as provided in this blend?

The equal 1:1 ratio is a common research convention but may not be pharmacologically optimal. TB-500's longer half-life means equal daily doses may lead to accumulation relative to BPC-157. Some researchers advocate a loading/maintenance protocol for TB-500 (e.g., 2 mg/week for 4 weeks loading, then 2 mg bi-weekly maintenance) while dosing BPC-157 daily. The fixed blend ratio limits this optimization, which is a legitimate reason advanced users sometimes prefer separate vials.

What does the animal evidence actually show for this combination?

Direct combination studies are sparse in published literature. BPC-157 alone has demonstrated healing benefits in tendon (Achilles, patellar), muscle crush injuries, ligament, bone, cornea, gut, and skin in rodent models across numerous studies from the Sikiric group and others (Journal of Physiology Paris, European Journal of Pharmacology). TB-500 (as Thymosin Beta-4) has strong animal evidence in cardiac repair, dermal wound healing, and corneal repair (Annals NYAS, multiple journals). The combination rationale is extrapolated from known independent mechanisms.

What is the evidence level?

This compound is classified as Animal data. Most data comes from preclinical animal studies. Human clinical trial evidence is limited or absent.

Research

Research & sources

Animal data

Current evidence for BPC-157 + TB-500 Blend (10mg + 10mg) is rated as Animal data. Research is based primarily on animal models.

1. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (2006) — Current Pharmaceutical Design, Sikiric et al.
2. BPC 157 and tendon healing: tendon fibroblast migration and proliferation (2015) — Journal of Physiology and Pharmacology
3. Thymosin Beta-4 and Ac-SDKP: actin sequestration and angiogenesis (2007) — Annals of the New York Academy of Sciences, Vol. 1112
4. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair (2004) — Nature, 432:466–472
5. BPC 157 and the vascular healing: VEGF upregulation and eNOS pathway (2016) — Current Medicinal Chemistry, related Sikiric group publications

Explore

Often discussed alongside

BPC-157 · healing TB-500 · healing GHK-Cu · skin Ipamorelin · growth CJC-1295 · growth IGF-1 LR3 · growth